We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Dr. Daniel Vitt is CEO of Immunic AG. He joined Immunic beginning of 2017 from 4SC AG, a publicly listed stock
company based in Martinsried, Germany which he co-founded in 1997. At 4SC he served as CSO and CDO. In this position he transformed 4SC from a research company into an advanced therapeutic development company and brought the company public on German stock exchange in Frankfurt in 2005.
As a member of the executive Board he was responsible for all research and development activities at 4SC group including four clinical stage products. In this position, he essentially contributed to 4SC’s maturing therapeutic pipeline and succeeded in bringing several projects. Among them Resminostat, 4SC-202 and IMU-838.
Daniel Vitt studied chemistry in Siegen and Würrzburg and graduated at the University of Würzburg in the group of G. Bringmann in quantumchemical calculations of organic reactions.
This speaker's sessions: